|Day Low/High||1.30 / 1.34|
|52 Wk Low/High||1.24 / 5.99|
New President and Chief Operating Officer Mr. Eric Curtis will be Representing CytRx Corporation
Seasoned Professional with 25 Years of Experience in Both Oncology and Orphan Diseases, Including Development and Commercialization of Approved Drugs Votrient®, Doxil®, Velcade® and Benlysta®
Supportive Data on All Candidates to be Highlighted in Poster Presentations at the Upcoming American Association for Cancer Research 2018 Annual Meeting Next Month
Company Engages Expert Advisor Eric L. Curtis to Lead Internal Development Efforts and Manage External Partner Relationships
All Three Studies Submitted Were Selected for Poster Presentations
Additional Clinical Trials Evaluating Combinations with Aldoxorubicin Expected to Commence in 2018
Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Hope springs eternal, until it's dashed on the rocks and buried at sea.
An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
Investors in CytRx Corp saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
TheStreet's biotech columnist offers his own report card on biotech stocks.
CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.